Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts

It is becoming clear that combination strategies will be necessary to augment cancer immunotherapy. We report that combination anti-OX40/anti-CTLA-4 mAb immunotherapy improves survival by enhancing effector T cell expansion and function, even while inducing Th2 cytokine production. Furthermore, IL-4...

Descripción completa

Detalles Bibliográficos
Autores principales: Linch, Stefanie N, Redmond, William L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091104/
https://www.ncbi.nlm.nih.gov/pubmed/25050194
http://dx.doi.org/10.4161/onci.28245
Descripción
Sumario:It is becoming clear that combination strategies will be necessary to augment cancer immunotherapy. We report that combination anti-OX40/anti-CTLA-4 mAb immunotherapy improves survival by enhancing effector T cell expansion and function, even while inducing Th2 cytokine production. Furthermore, IL-4 blockade in addition to combination therapy significantly improved anti-tumor efficacy.

Ejemplares similares